Shaji Kumar, MD

Articles

Emerging Biomarkers in Multiple Myeloma

August 18th 2022

Shaji Kumar, MD, talks about new biomarkers that are being explored in patients with multiple myeloma.

Evidence Around Venetoclax for Patients with t(11;14) Translocation in MM

August 18th 2022

Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of venetoclax for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.

Role of t(11;14) Translocation in Patients with MM

August 10th 2022

Dr Shaji Kumar explains the role of t(11;14) translocation in patients with multiple myeloma and discusses treatment options for this specific population.

Biomarkers in Multiple Myeloma (MM): Overview

August 10th 2022

Jonathan Kaufman, MD, provides an overview of multiple myeloma (MM) and reviews current biomarkers and molecular pathways commonly seen in MM.

Dr. Kumar on Integrating CAR T-Cell Therapy Into Heavily Pretreated Multiple Myeloma

July 13th 2021

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

Dr. Kumar on the Evolving Role of Venetoclax in Relapsed/Refractory Multiple Myeloma

April 1st 2021

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

Dr. Kumar on Understanding the Safety Profiles of Combination Therapies in Multiple Myeloma

January 15th 2021

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Dr. Kumar on the Rationale Behind the ENDURANCE Trial in Newly Diagnosed Myeloma

July 10th 2020

Shaji Kumar, MD, discusses the rationale behind the phase 3 ENDURANCE trial, which is comparing carfilzomib, lenalidomide, and dexamethasone with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Dr. Kumar on Utility of ASCT in Newly Diagnosed Multiple Myeloma

February 22nd 2019

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

Dr. Kumar on Updates to Treatment for Patients With High-Risk Myeloma

November 9th 2017

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.

Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma

May 2nd 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

Dr. Kumar on Recent Advancements in the Field of Multiple Myeloma

April 27th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses some of the recent advancements, including FDA approvals, in the field of multiple myeloma.

Dr. Kumar on the Safety and Efficacy of Venetoclax in Myeloma

January 24th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the safety profile and the survival benefits associated with venetoclax in the treatment of patients with multiple myeloma.

Dr. Shaji Kumar on New Criteria for Response and MRD Assessment in Multiple Myeloma

October 19th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the International Myeloma Working Group’s recently released updated consensus criteria for response and minimal residual disease (MRD) assessment in multiple myeloma.

Dr. Shaji Kumar on MRD in Multiple Myeloma

October 11th 2016

Shaji Kumar, MD, professor of Medicine at Mayo Clinic, discusses how minimal residual disease (MRD) testing has evolved in multiple myeloma.

Dr. Kumar Discusses the Role of Stem Cell Transplant in Multiple Myeloma

September 10th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the role of stem cell transplant in treating patients with multiple myeloma.

Dr. Shaji Kumar on Upfront Combination Treatments in Multiple Myeloma

August 16th 2016

​Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.